Last 47 quarters of trend data · Healthcare · Immunology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 21.31 | 274.70 | 69.21 | 53.23 | 3.72 | 52.93 | 316.96 | 50.17 | 292.38 | 102.95 | — | — | 2.86 | — | — | — | — | — | — | — | — |
| — | +419.0% | -78.2% | +6.1% | -98.7% | -48.6% | — | — | +10112.1% | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 11.46 | 8.99 | 6.49 | 6.17 | 8.99 | 10.36 | 13.28 | 11.15 | 11.20 | 9.65 | 8.76 | 13.90 | 1.96 | 54.67 | 67.61 | 5068.74 | 2130.68 | 246.45 | 158.50 | 271.28 | 542.45 |
| — | -13.3% | -51.1% | -44.7% | -19.7% | +7.4% | +51.6% | -19.8% | +470.3% | -82.3% | -87.0% | -99.7% | -99.9% | -77.8% | -57.3% | +1768.4% | +292.8% | -70.3% | -92.1% | -99.4% | -97.4% | |
| P/B Ratio | 14.90 | 14.30 | 9.12 | 7.33 | 9.58 | 21.16 | 27.05 | 21.69 | 19.56 | 15.97 | 13.89 | 15.23 | 7.91 | 86.89 | 76.93 | 27.69 | 7.97 | 4.54 | 7.50 | 10.62 | 14.14 |
| — | -32.4% | -66.3% | -66.2% | -51.0% | +32.5% | +94.7% | +42.4% | +147.4% | -81.6% | -81.9% | -45.0% | -0.8% | +1814.7% | +925.5% | +160.7% | -43.6% | -66.1% | -47.5% | -14.6% | -24.3% | |
| P/FCF | 526.83 | 55.43 | — | 60.62 | — | 197.81 | — | — | — | 128.08 | — | — | 3.89 | — | — | — | — | — | — | — | — |
| — | -72.0% | — | — | — | +54.4% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 68.36 | 102.35 | 40.35 | 24.39 | 50.94 | 42.80 | 188.39 | 40.79 | 76.35 | 80.61 | — | — | 2.75 | — | — | — | — | — | — | — | — |
| — | +139.1% | -78.6% | -40.2% | -33.3% | -46.9% | — | — | +2680.7% | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 75.74 | 102.81 | 50.20 | 23.88 | 45.94 | 39.69 | 133.73 | 37.65 | 63.20 | 68.05 | — | — | 2.68 | — | — | — | — | — | — | — | — |
| — | +159.0% | -62.5% | -36.6% | -27.3% | -41.7% | — | — | +2256.3% | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.7% | 82.9% | 83.6% | 80.2% | 82.6% | 86.6% | 87.1% | 85.8% | 88.9% | 88.7% | 91.3% | 81.9% | 97.9% | 88.1% | 89.0% | 96.3% | 97.9% | 96.1% | 88.2% | 91.0% | 85.6% |
| — | -4.3% | -4.0% | -6.5% | -7.1% | -2.4% | -4.6% | +4.7% | -9.2% | +0.7% | +2.6% | -14.9% | +0.0% | -8.3% | +0.9% | +5.8% | +14.3% | +6.3% | +7.0% | +150.8% | -14.4% | |
| Operating Margin | 20.0% | 9.0% | 17.0% | 26.2% | 18.2% | 24.7% | 7.1% | 27.7% | 14.8% | 12.0% | -14.6% | -28.4% | 69.2% | -277.9% | -474.1% | -65077.5% | -37194.7% | -6555.7% | -3317.1% | -4004.6% | -4193.5% |
| — | -63.5% | +138.0% | -5.3% | +22.5% | +105.7% | +148.8% | +197.5% | -78.6% | +104.3% | +96.9% | +100.0% | +100.2% | +95.8% | +85.7% | -1525.1% | -787.0% | -30.7% | +70.5% | +98.2% | +98.1% | |
| Net Margin | 72.6% | 3.2% | 9.7% | 12.0% | 241.7% | 20.0% | 4.2% | 21.6% | 4.6% | 9.4% | -16.9% | -32.8% | 68.7% | -296.2% | -502.8% | -66242.5% | -38104.3% | -6819.9% | -3423.3% | -4021.5% | -4218.6% |
| — | -83.8% | +130.5% | -44.5% | +5125.7% | +113.3% | +124.8% | +165.8% | -93.3% | +103.2% | +96.6% | +100.0% | +100.2% | +95.7% | +85.3% | -1547.2% | -803.3% | -34.2% | +70.0% | +98.3% | +98.2% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 102.8% | 1.3% | 3.2% | 3.7% | 88.5% | 11.0% | 2.2% | 11.3% | 2.1% | 4.1% | -6.7% | -8.9% | 111.0% | -140.3% | -91.2% | -66.6% | -31.2% | -27.1% | -33.9% | -34.0% | -24.7% |
| — | -88.1% | +45.9% | -67.4% | +4115.2% | +169.3% | +133.0% | +227.0% | -98.1% | +102.9% | +92.7% | +86.7% | +455.7% | -418.4% | -169.3% | -95.8% | -26.6% | -42.8% | -80.2% | -33.1% | +48.4% | |
| ROA | 54.5% | 0.5% | 1.5% | 2.2% | 45.3% | 4.1% | 0.8% | 4.0% | 0.8% | 1.8% | -3.0% | -4.4% | 41.3% | -22.8% | -20.1% | -25.8% | -15.3% | -14.6% | -20.2% | -23.7% | -19.2% |
| — | -88.2% | +86.1% | -45.0% | +5657.3% | +133.5% | +126.9% | +191.9% | -98.1% | +107.8% | +84.8% | +83.1% | +370.6% | -55.9% | +0.7% | -8.9% | +20.6% | +4.2% | -31.0% | -20.6% | +37.3% | |
| ROIC | 16.4% | 1.8% | 3.0% | 4.7% | 3.7% | 6.9% | 2.0% | 8.2% | 4.1% | 3.3% | -3.7% | -6.2% | 97.7% | -53.0% | -48.9% | -69.6% | -38.8% | -46.3% | -123.7% | -467.8% | -444.0% |
| — | -73.3% | +53.3% | -43.0% | -9.1% | +109.9% | +153.2% | +232.7% | -95.8% | +106.2% | +92.4% | +91.1% | +351.9% | -14.3% | +60.5% | +85.1% | +91.3% | +87.2% | +78.1% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.40 | 1.25 | 1.29 | 0.40 | 0.42 | 0.92 | 1.07 | 1.14 | 1.32 | 0.63 | 0.70 | 0.69 | 0.67 | 2.69 | 3.94 | 1.42 | 0.82 | 0.62 | 0.46 | 0.33 | 0.09 |
| — | +36.1% | +20.9% | -64.7% | -68.4% | +44.8% | +53.3% | +65.3% | +98.0% | -76.5% | -82.3% | -51.3% | -18.5% | +332.5% | +749.5% | +325.3% | +827.5% | +585.2% | +391.8% | +312.4% | -63.3% | |
| Debt / EBITDA | 2.11 | 34.66 | 21.61 | 5.16 | 8.62 | 7.27 | 29.24 | 8.45 | 20.31 | 12.66 | — | — | 0.96 | — | — | — | — | — | — | — | — |
| — | +376.7% | -26.1% | -39.0% | -57.5% | -42.6% | — | — | +2023.2% | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.10 | 4.27 | 5.81 | 4.10 | 3.82 | 3.86 | 4.02 | 6.25 | 4.59 | 3.58 | 3.62 | 5.92 | 5.53 | 2.87 | 2.93 | 3.16 | 5.02 | 4.68 | 4.43 | 5.06 | 4.24 |
| — | +10.5% | +44.4% | -34.3% | -16.6% | +7.9% | +11.2% | +5.5% | -17.1% | +24.8% | +23.5% | +87.1% | +10.2% | -38.6% | -33.9% | -37.5% | +18.3% | -10.1% | -23.4% | -27.6% | +26.5% | |
| Quick Ratio | 3.29 | 3.72 | 5.12 | 3.29 | 2.89 | 2.96 | 3.04 | 5.03 | 3.91 | 2.83 | 2.84 | 5.18 | 4.95 | 2.45 | 2.50 | 3.16 | 5.02 | 4.68 | 4.43 | 5.06 | 4.24 |
| — | +25.5% | +68.5% | -34.7% | -26.2% | +4.5% | +7.1% | -2.9% | -21.0% | +15.5% | +13.6% | +63.7% | -1.4% | -47.5% | -43.6% | -37.5% | +18.3% | -10.1% | -23.4% | -27.6% | +26.5% | |
| Interest Coverage | 5.02 | 1.31 | 3.66 | 7.90 | 4.85 | 5.60 | 1.81 | 4.60 | 1.39 | 2.65 | -3.67 | -4.77 | 31.68 | -12.13 | -12.79 | -17.52 | -20.73 | -12.43 | -24.91 | -85.50 | -81.50 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TGTX stock.
TG Therapeutics, Inc.'s current P/E is 21.3x. The average P/E over the last 4 quarters is 100.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
TG Therapeutics, Inc.'s current operating margin is 20.0%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking TG Therapeutics, Inc.'s business trajectory between earnings reports.